Accuray Inc

Accuray insider buys 650k RSUs, signaling long‑term commitment and investor confidence, yet market buzz remains muted as the company navigates reimbursement and growth challenges.

TCW Group’s 18.9 million warrant acquisition signals optimism for Accuray’s expanding Radixact oncology platform, highlighting future regulatory approvals, clinical gains, and potential dilution impacts on investors.

Accuray insider activity shows senior execs selling vested RSUs for liquidity while buying shares for upside, reflecting confidence in a profitable transformation plan.